MAM
First Indian outdoor advertising meet in June
MUMBAI: The great outdoors just got more exciting. Outdoor Today, which claims to be India’s only magazine on outdoor advertising, has announced the launch of an annual convention for the outdoor advertising community in the country.
The two-day event, Outdoor Advertising Convention (OAC 2005) on 10 and 11 June 2005 in Mumbai will bring together experts from the industry in India and abroad.
The aim is to address issues of relevance. The event will end in an awards ceremony.
Outdoor Today publisher Vasant Jante says, “Outdoor Advertising is no longer just a ‘brush and paint’ medium. In fact, the medium has seen resurgence the world over and is also being touted as the last broadcast medium.
“When we launched Outdoor Today in 2002, the objective was to provide a forum for the Outdoor industry that is growing at a healthy 10 per cent. OAC 2005 is the next logical step in that direction.”
OAC 2005 will comprise a series of interactive seminars addressed by thought leaders from India and abroad.
The delegates would comprise all interest groups in the industry including media planning and buying agencies, advertising agencies, outdoor specialists, outdoor concessionaires, regulatory authorities, research agencies etc.
The speakers will address the entire range of issues that are of relevance to the industry, including research, regulation, innovation, technology, creativity etc.
The two-day event would culminate in an awards ceremony to recognise exceptional creative executions on the outdoor medium – another first for the industry.
The event is being supported by the recently constituted Indian Outdoor Advertising Agencies’ Association (IOAAA), an association of all specialist agencies in the country.
Outdoor Today states that specialist agencies currently account for over 60 per cent of the outdoor spends in the country and have been largely instrumental in bringing a semblance of order to a medium considered disorganised for long
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
